CervoMed (CRVO) stock price, chart and financials
Price chart
Financials
- Revenue (trailing twelve months)
- $331,295.00
- Revenue growth (year over year)
- −100.00%
- Gross profit (trailing twelve months)
- $331,295.00
- Gross margin
- 100.00%
- Net income (quarter)
- −$6.6M
- Net margin
- −9160.94%
- Return on equity
- −107.62%
- Book value per share
- $1.70
- Price to book
- 1.49
- Debt to assets
- 11.67%
Company profile
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Frequently asked questions
Is CervoMed (CRVO) profitable?
No. CervoMed reported a net loss of $30.3M over the trailing twelve months.
How much revenue does CervoMed (CRVO) make?
CervoMed generated $331,295.00 in revenue over the trailing twelve months, down 100.00% year over year.
How do I buy stock in CervoMed (CRVO)?
CRVO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.